Cargando…

Current status of theranostics in prostate cancer

The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of (68)Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Virgolini, Irene, Decristoforo, Clemens, Haug, Alexander, Fanti, Stefano, Uprimny, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787224/
https://www.ncbi.nlm.nih.gov/pubmed/29282518
http://dx.doi.org/10.1007/s00259-017-3882-2
_version_ 1783295890334679040
author Virgolini, Irene
Decristoforo, Clemens
Haug, Alexander
Fanti, Stefano
Uprimny, Christian
author_facet Virgolini, Irene
Decristoforo, Clemens
Haug, Alexander
Fanti, Stefano
Uprimny, Christian
author_sort Virgolini, Irene
collection PubMed
description The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of (68)Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA radioligand therapy (PRLT) in castration-resistant (CR)PC is assessed. The most eminent data from mostly retrospective studies currently available on theranostics of prostate cancer are discussed. The current knowledge on (68)Ga-PSMA PET/CT implicates that primary staging with PET/CT is meaningful in patients with high-risk PC and that the combination with pelvic multi parametric (mp)MR (or PET/mpMR) reaches the highest impact on patient management. There may be a place for (68)Ga-PSMA PET/CT in intermediate-risk PC patients as well, however, only a few data are available at the moment. In secondary staging for local recurrence, (68)Ga-PSMA PET/mpMR is superior to PET/CT, whereas for distant recurrence, PET/CT has equivalent results and is faster and cheaper compared to PET/mpMR. (68)Ga-PSMA PET/CT is superior to (18)F / (11)Choline PET/CT in primary staging as well as in secondary staging. In patients with biochemical relapse, PET/CT positivity is directly associated with prostate-specific antigen (PSA) increase and amounts to roughly 50% when PSA is raised to ≤0.5 ng/ml and to ≥90% above 1 ng/ml. Significant clinical results have so far been achieved with the subsequent use of radiolabeled PSMA ligands in the treatment of CRPC. Accumulated activities of 30 to 50 GBq of (177)Lu-PSMA ligands seem to be clinically safe with biochemical response and PERCIST/RECIST response in around 75% of patients along with xerostomia in 5–10% of patients as the only notable side effect. On the basis of the current literature, we conclude that PSMA-directed theranostics do have a major clinical impact in diagnosis and therapy of PC patients. We recommend that (68)Ga-PSMA PET/CT should be performed in primary staging together with pelvic mpMR in high-risk patients and in all patients for secondary staging, and that PSMA-directed therapy is a potent strategy in CRPC patients when other treatment options have failed. The combination of PSMA-directed therapy with existing therapy modalities (such as (223)Ra-chloride or androgen deprivation therapy) has to be explored, and prospective clinical multicenter trials with theranostics are warranted.
format Online
Article
Text
id pubmed-5787224
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-57872242018-02-02 Current status of theranostics in prostate cancer Virgolini, Irene Decristoforo, Clemens Haug, Alexander Fanti, Stefano Uprimny, Christian Eur J Nucl Med Mol Imaging Review Article The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of (68)Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA radioligand therapy (PRLT) in castration-resistant (CR)PC is assessed. The most eminent data from mostly retrospective studies currently available on theranostics of prostate cancer are discussed. The current knowledge on (68)Ga-PSMA PET/CT implicates that primary staging with PET/CT is meaningful in patients with high-risk PC and that the combination with pelvic multi parametric (mp)MR (or PET/mpMR) reaches the highest impact on patient management. There may be a place for (68)Ga-PSMA PET/CT in intermediate-risk PC patients as well, however, only a few data are available at the moment. In secondary staging for local recurrence, (68)Ga-PSMA PET/mpMR is superior to PET/CT, whereas for distant recurrence, PET/CT has equivalent results and is faster and cheaper compared to PET/mpMR. (68)Ga-PSMA PET/CT is superior to (18)F / (11)Choline PET/CT in primary staging as well as in secondary staging. In patients with biochemical relapse, PET/CT positivity is directly associated with prostate-specific antigen (PSA) increase and amounts to roughly 50% when PSA is raised to ≤0.5 ng/ml and to ≥90% above 1 ng/ml. Significant clinical results have so far been achieved with the subsequent use of radiolabeled PSMA ligands in the treatment of CRPC. Accumulated activities of 30 to 50 GBq of (177)Lu-PSMA ligands seem to be clinically safe with biochemical response and PERCIST/RECIST response in around 75% of patients along with xerostomia in 5–10% of patients as the only notable side effect. On the basis of the current literature, we conclude that PSMA-directed theranostics do have a major clinical impact in diagnosis and therapy of PC patients. We recommend that (68)Ga-PSMA PET/CT should be performed in primary staging together with pelvic mpMR in high-risk patients and in all patients for secondary staging, and that PSMA-directed therapy is a potent strategy in CRPC patients when other treatment options have failed. The combination of PSMA-directed therapy with existing therapy modalities (such as (223)Ra-chloride or androgen deprivation therapy) has to be explored, and prospective clinical multicenter trials with theranostics are warranted. Springer Berlin Heidelberg 2017-12-28 2018 /pmc/articles/PMC5787224/ /pubmed/29282518 http://dx.doi.org/10.1007/s00259-017-3882-2 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Virgolini, Irene
Decristoforo, Clemens
Haug, Alexander
Fanti, Stefano
Uprimny, Christian
Current status of theranostics in prostate cancer
title Current status of theranostics in prostate cancer
title_full Current status of theranostics in prostate cancer
title_fullStr Current status of theranostics in prostate cancer
title_full_unstemmed Current status of theranostics in prostate cancer
title_short Current status of theranostics in prostate cancer
title_sort current status of theranostics in prostate cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787224/
https://www.ncbi.nlm.nih.gov/pubmed/29282518
http://dx.doi.org/10.1007/s00259-017-3882-2
work_keys_str_mv AT virgoliniirene currentstatusoftheranosticsinprostatecancer
AT decristoforoclemens currentstatusoftheranosticsinprostatecancer
AT haugalexander currentstatusoftheranosticsinprostatecancer
AT fantistefano currentstatusoftheranosticsinprostatecancer
AT uprimnychristian currentstatusoftheranosticsinprostatecancer